- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
- Novartis: CEO needs to convince over long-term prospects
- Pharmaceutical industry close to deal with UK on drug pricing, says Novartis
- Novartis plans to spin off Sandoz in October
- Novartis boss warns US drug pricing reform poses risk to public health
- Novartis plans $15bn buyback after failing to find deals
More ▼
Key statistics
On Thursday, Novartis AG (0QLR:LSE) closed at 89.19, -5.62% below its 52-week high of 94.50, set on Jan 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 89.07 |
---|---|
High | -- |
Low | -- |
Bid | 86.96 |
Offer | 91.41 |
Previous close | 88.84 |
Average volume | 519.91k |
---|---|
Shares outstanding | 2.19bn |
Free float | 2.10bn |
P/E (TTM) | 21.96 |
Market cap | 194.19bn CHF |
EPS (TTM) | 4.04 CHF |
Annual div (ADY) | 3.30 CHF |
---|---|
Annual div yield (ADY) | 3.71% |
Div ex-date | Mar 07 2024 |
Div pay-date | Mar 11 2024 |
Data delayed at least 20 minutes, as of May 02 2024 17:08 BST.
More ▼